CYP2B6 and type 2 diabetes mellitus: Whether to use antiplatelet therapy for patients with type 2 diabetes, this is still a debated issue, because more and more patients are resistant to aspirin [46, 47], which may be due to the imbalance between pro-anti-inflammatory and anti-inflammatory cytokines caused by the changes of P450 genotype in the cytochrome.